Core Insights - Candel Therapeutics Inc's investigational medicine CAN-2409 shows promising results in a phase 2 trial for borderline resectable pancreatic cancer, with a median overall survival of 31.4 months compared to 12.5 months in the control group [2][7] - The treatment has demonstrated a significant breakthrough potential for patients with typically poor prognoses, as standard survival rates for this cancer type range from 6 to 12 months [3][9] - The company aims to confirm these results in a larger randomized controlled clinical trial, with hopes for FDA approval and potential testing in other stages of pancreatic cancer [10][11] Treatment Details - The phase 2 trial involved patients with borderline resectable pancreatic cancer, where tumors invade blood vessels, making surgery unfeasible initially [5] - All patients received standard chemotherapy followed by chemoradiation, with the active treatment group receiving 2 to 3 doses of CAN-2409 [6][10] - Notably, three out of seven patients in the treatment group remained alive after prolonged follow-up, with two patients exceeding five years of survival [2][8] Future Prospects - The company has received fast track designation and orphan drug designation from the FDA, which will facilitate the development process [11] - There is a strong motivation within the company to improve patient outcomes and create value for shareholders through advancements in oncology [12][13]
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI